Bayer has set up a system to manage its omics data analysis workflow. The system is the result of Bayer's collaboration with Genedata, which has provided its data management and analysis software to a platform that also draws on the capabilities of the open-source iRODS.
Pairing the two software packages is intended to create a system that facilitates the sharing of data, including between teams on either side of the preclinical-clinical divide, without compromising its security or the privacy of patients. With Bayer hitching the future of its business to life sciences--and the success of R&D being tied increasingly to the ability to parse omics data--the capabilities of the system could have a notable effect on the future of the increasingly slimline German conglomerate. Genedata is confident Bayer has a package to support the next iteration of the company.
"Our successful collaboration with Bayer Pharma AG has resulted in the establishment of a state-of-the-art translational research data platform that allows interdisciplinary and geographically dispersed teams of researchers to work with patient-related [next-generation sequencing] data," Genedata CEO Othmar Pfannes said in a statement. "This solution ensures that only properly authenticated and authorized researchers have access to this sensitive information." Such features are central to the sales pitch for Genedata's precision medicine-focused Profiler software.
Bayer is among the early adopters of the software, which was unveiled in April. Genedata is positioning the software as a way for drug developers to automate the processing of NGS data, pull in results from different sources without compromising compliance and then dig into and visualize the resource using custom or public algorithms. Bayer's interest in the system has contributed to a busy year for Genedata, which also persuaded Boehringer Ingelheim and Merck Serono to sign up to use its Biologics antibody-discovery platform.
- read the release
Special Report: 10 Next-Gen Biologics Platforms